Exchange Traded Concepts LLC Buys 122 Shares of Medpace Holdings, Inc. $MEDP

Exchange Traded Concepts LLC boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.7% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,727 shares of the company’s stock after buying an additional 122 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Medpace were worth $856,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in Medpace by 37.1% during the first quarter. GAMMA Investing LLC now owns 307 shares of the company’s stock valued at $94,000 after buying an additional 83 shares during the period. Inspire Investing LLC purchased a new stake in Medpace during the first quarter valued at about $2,059,000. Voya Investment Management LLC lifted its holdings in Medpace by 7.6% during the first quarter. Voya Investment Management LLC now owns 21,976 shares of the company’s stock valued at $6,696,000 after purchasing an additional 1,560 shares during the last quarter. Zeno Equity Partners LLP lifted its holdings in Medpace by 2.6% during the first quarter. Zeno Equity Partners LLP now owns 62,304 shares of the company’s stock valued at $18,983,000 after purchasing an additional 1,564 shares during the last quarter. Finally, United Services Automobile Association purchased a new stake in Medpace during the first quarter valued at about $500,000. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Down 0.4%

Shares of Medpace stock opened at $496.14 on Wednesday. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $506.55. The company has a market cap of $13.94 billion, a price-to-earnings ratio of 36.89, a PEG ratio of 3.13 and a beta of 1.44. The company’s 50-day moving average price is $454.11 and its 200-day moving average price is $357.57.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.10. The company had revenue of $603.31 million for the quarter, compared to analysts’ expectations of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. Medpace’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on MEDP shares. Jefferies Financial Group upped their price objective on shares of Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a report on Tuesday, September 9th. Barclays upped their price objective on shares of Medpace from $300.00 to $450.00 and gave the company an “equal weight” rating in a report on Wednesday, July 23rd. Truist Financial upped their price objective on shares of Medpace from $298.00 to $436.00 and gave the company a “hold” rating in a report on Wednesday, July 23rd. Robert W. Baird upped their price objective on shares of Medpace from $313.00 to $490.00 and gave the company a “neutral” rating in a report on Wednesday, July 23rd. Finally, Cowen downgraded shares of Medpace from a “buy” rating to a “sell” rating in a report on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Medpace presently has an average rating of “Reduce” and an average target price of $422.27.

Insider Buying and Selling

In related news, President Jesse J. Geiger sold 41,801 shares of the company’s stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $453.11, for a total value of $18,940,451.11. Following the transaction, the president directly owned 36,503 shares in the company, valued at approximately $16,539,874.33. This represents a 53.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Kevin M. Brady sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the completion of the transaction, the chief financial officer owned 6,000 shares in the company, valued at approximately $2,725,380. This trade represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 161,266 shares of company stock valued at $74,111,427 in the last 90 days. 20.30% of the stock is owned by company insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.